🔍

VINEETLAB - Vineet Laborator

📊 NSE: VINEETLAB 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 15:08

📢 Recent Corporate Announcements

Vineet Laboratories Exempt from Q4 FY26 Corporate Governance Reporting

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 29 Apr 2026, 05:11 PM

Vineet Laboratories Limited has submitted a certificate of non-applicability for Corporate Governance reporting for the quarter ended March 31, 2026. Under SEBI Regulation 15(2), companies with paid-up capital under ₹10 crore and net worth under ₹25 crore are exempt from these specific filings. As of March 31, 2025, the company reported a paid-up capital of ₹9.22 crore and a net worth of ₹3.30 crore. This disclosure confirms the company's status as a smaller listed entity with reduced regulatory reporting requirements.

Paid-up equity share capital stood at ₹9,21,90,080 as of March 31, 2025
Company net worth was reported at ₹3,29,52,887 as of March 31, 2025
Exemption claimed under Regulation 15(2) of SEBI (LODR) Regulations, 2015
Thresholds for exemption are paid-up capital below ₹10 Cr and net worth below ₹25 Cr

💡 No action is required as this is a routine regulatory filing confirming the company's small-cap compliance status. Investors should remain aware that smaller entities have fewer disclosure obligations compared to larger listed firms.

Vineet Laboratories Reports Q4 FY26 SDD Compliance with 1 UPSI Event Captured

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 21 Apr 2026, 07:19 PM

Vineet Laboratories Limited has submitted its quarterly compliance certificate for the Structured Digital Database (SDD) for the quarter ended March 31, 2026. The company confirmed adherence to SEBI (Prohibition of Insider Trading) Regulations, ensuring that all Unpublished Price Sensitive Information (UPSI) is tracked. During the fourth quarter, the company identified and recorded 1 specific UPSI event in its internal database. This filing confirms that the database is non-tamperable and maintains an audit trail for the required 8-year period.

Confirmed compliance with Regulations 3(5) and 3(6) of SEBI (PIT) Regulations, 2015
Successfully captured 1 UPSI event during the fourth quarter ended March 31, 2026
Maintains an internal, non-tamperable database with an 8-year audit trail capability
Reported zero non-compliances for the period under review

💡 This is a routine regulatory filing indicating the company is following standard corporate governance procedures. No immediate action is required from investors.

Vineet Laboratories Reports Zero Demat Requests in Q4 FY2026 Compliance Filing

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Apr 2026, 07:12 PM

Vineet Laboratories Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by the Registrar and Share Transfer Agent (RTA), covers the fourth quarter and the full financial year ended March 31, 2026. The RTA confirmed that zero securities were received for dematerialization or rematerialization during this period. This is a standard administrative filing required by all listed companies in India to ensure share records match depository data.

Compliance certificate submitted for the quarter and financial year ended March 31, 2026.
Registrar (RTA) confirmed that 0 securities were received for dematerialization or rematerialization during the quarter.
The filing fulfills mandatory requirements under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

💡 No action is required as this is a routine administrative filing. Investors should focus on upcoming earnings reports for material performance updates.

Vineet Laboratories Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Mar 2026, 04:54 PM

Vineet Laboratories Limited has informed the exchanges that its trading window will be closed starting April 1, 2026. This closure is in preparation for the announcement of the audited financial results for the fourth quarter and the full financial year ending March 31, 2026. The window will remain shut for all designated persons and their relatives until 48 hours after the results are declared. The company has also confirmed the freezing of PANs for designated persons as per SEBI regulations.

Trading window closure commences on April 1, 2026
Applies to the fourth quarter and financial year ending March 31, 2026
Window to reopen 48 hours after the announcement of audited financial results
PAN freezing implemented for all Designated Persons (DPs) and immediate relatives

💡 This is a routine regulatory announcement; no immediate action is required. Investors should monitor for the upcoming board meeting date to review the company's annual financial performance.

Vineet Laboratories Q3 Results: PAT at ₹85.07 Lakhs, Turnaround from YoY Loss

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 14 Feb 2026, 04:14 PM

Vineet Laboratories reported a net profit of ₹85.07 Lakhs for the quarter ended December 31, 2025, marking a significant turnaround from a net loss of ₹570.70 Lakhs in the same period last year. Although revenue from operations declined by 13.5% YoY to ₹1,564.83 Lakhs, the company achieved profitability through improved cost efficiencies. For the nine-month period, the company turned profitable with a PAT of ₹38.56 Lakhs compared to a loss of ₹966.61 Lakhs in the previous year. The board also ratified payments for new equipment intended for the production facility mentioned in their recent Rights Issue.

Net Profit of ₹85.07 Lakhs in Q3 FY26 vs a loss of ₹570.70 Lakhs in Q3 FY25
Revenue from operations stood at ₹1,564.83 Lakhs, down from ₹1,809.93 Lakhs YoY
Nine-month (9M) PAT turned positive at ₹38.56 Lakhs against a loss of ₹966.61 Lakhs in 9M FY25
Earnings Per Share (EPS) improved to ₹0.92 from a negative ₹6.19 YoY
Board ratified advances for Quality Control and RO equipment for a new production facility

💡 The company has successfully transitioned back to profitability despite a declining top line, suggesting improved operational margins. Investors should watch for revenue scaling once the new production facility and equipment are fully operational.

Vineet Laboratories Appoints Ms. Jasmin Kunal Tailor as Independent Director with 99.99% Approval

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 07 Feb 2026, 05:18 PM

Vineet Laboratories Limited successfully passed a special resolution during its Extra-Ordinary General Meeting held on February 07, 2026. The resolution pertained to the appointment of Ms. Jasmin Kunal Tailor as an Independent Director of the company. The proposal received overwhelming support, with 99.99% of the total votes cast in favor. Although the promoter group participated fully, the overall shareholder turnout was approximately 13.23% of the total equity base.

Special resolution for the appointment of Ms. Jasmin Kunal Tailor as Independent Director passed with 99.9936% majority.
A total of 1,219,294 votes were polled out of a total share capital of 9,219,008 shares.
Promoter and Promoter Group cast 1,147,322 votes, all of which were 100% in favor of the resolution.
Public non-institutional investors cast 71,972 votes, with 99.89% in favor and only 78 votes against.
The meeting was conducted via video conferencing with 51 shareholders in attendance.

💡 This is a routine governance update and does not require any immediate portfolio changes. Investors should continue to monitor the company's operational performance and any strategic shifts resulting from the board's new composition.

Vineet Laboratories Appoints Jasmin Kunal Tailor as Independent Director at EGM

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 07 Feb 2026, 05:08 PM

Vineet Laboratories Limited held an Extraordinary General Meeting (EGM) on February 07, 2026, primarily to approve the appointment of Ms. Jasmin Kunal Tailor as an Independent Director. The meeting was attended by 51 members through video conferencing and involved a special resolution for the appointment. Remote e-voting was conducted between February 04 and February 06, 2026, prior to the meeting. The final voting results will be declared and submitted to the stock exchanges within the prescribed timelines.

Extraordinary General Meeting (EGM) held on February 07, 2026, with 51 members attending via VC/OAVM.
Proposed a Special Resolution for the appointment of Ms. Jasmin Kunal Tailor (DIN: 10794164) as an Independent Director.
Remote e-voting period spanned from 9:00 A.M. on February 04 to 5:00 P.M. on February 06, 2026.
The meeting concluded at 11:45 A.M. IST, including the time allowed for electronic voting at the venue.
Mr. Jineshwar Kumar Sankhala was appointed as the Scrutinizer to oversee the voting process.

💡 This is a routine governance matter regarding board composition. Investors should monitor the final voting results to confirm the appointment but no immediate portfolio action is necessary.

Vineet Laboratories Gets Trading Approval for 99.87 Lakh Rights Issue Shares

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 04 Feb 2026, 06:46 PM

Vineet Laboratories Limited has received final trading approvals from both BSE and NSE for 99,87,258 equity shares allotted under its recent Rights Issue. These shares, issued at a price of Rs. 30 each (Rs. 10 face value plus Rs. 20 premium), are set to commence trading on February 05, 2026. This announcement marks the successful completion of the fundraising process, providing liquidity to the newly issued shares. Investors should be aware that the total outstanding equity has increased, which may lead to dilution of earnings per share (EPS).

Received trading approval for 99,87,258 equity shares from BSE and NSE.
Shares issued at Rs. 30 per share, including a premium of Rs. 20.
Trading of the new shares is effective from Thursday, February 05, 2026.
Distinctive numbers for the new shares range from 9219009 to 19206266.

💡 Shareholders who were allotted shares in the rights issue can now trade them on the exchanges. Monitor the stock for potential short-term price volatility as the new supply of shares enters the secondary market.

Vineet Laboratories Allots 99.87 Lakh Equity Shares via Rights Issue at Rs 30 Per Share

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 02 Feb 2026, 05:56 PM

Vineet Laboratories has successfully completed its rights issue by allotting 99,87,258 equity shares at a price of Rs 30 per share (including a premium of Rs 20). This capital infusion has raised approximately Rs 29.96 crore for the company. Consequently, the total paid-up equity share capital has more than doubled, increasing from Rs 9.22 crore to Rs 19.21 crore. The allotment follows the terms set in the Letter of Offer dated December 17, 2025.

Allotment of 99,87,258 equity shares of face value Rs 10 each on a rights basis.
Issue price fixed at Rs 30 per share, representing a total fundraise of approx Rs 29.96 crore.
Total number of equity shares increased from 92,19,008 to 1,92,06,266 post-allotment.
Paid-up share capital expanded from Rs 9,21,90,080 to Rs 19,20,62,660.
The allotment was finalized in consultation with Bigshare Services Private Limited and BSE Limited.

💡 Investors should track the company's upcoming quarterly results to see how the newly raised capital is deployed for growth. While the capital infusion is positive, shareholders should be aware of the significant equity dilution as the share count has more than doubled.

Vineet Laboratories Extends Rights Issue Closing Date to January 30, 2026

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 13 Jan 2026, 01:18 PM

Vineet Laboratories Limited has announced an extension of its ongoing Rights Issue timeline following a committee meeting on January 13, 2026. The last date for On-Market Renunciation has been moved to January 27, 2026, while the overall Issue Closing Date is now January 30, 2026. This extension is intended to provide more time for investors to participate in the fundraising process. Following the closure, the basis of allotment and listing of shares are scheduled for February 2 and February 3, 2026, respectively.

Last date for On-Market Renunciation of Rights Entitlements extended to January 27, 2026
Rights Issue closing date officially extended to January 30, 2026
Basis of Allotment and Allotment of Shares scheduled for February 2, 2026
Listing of new Equity Shares on BSE and NSE expected by February 3, 2026

💡 Investors holding Rights Entitlements (REs) should ensure they either subscribe to the issue or sell their REs on the market by January 27 to avoid total value loss. Monitor the share price relative to the rights price to determine if subscription is financially viable.

Vineet Laboratories Schedules EGM for Feb 7, 2026, to Appoint Independent Director

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 12 Jan 2026, 03:50 PM

Vineet Laboratories Limited has called for an Extra-Ordinary General Meeting (EGM) on February 07, 2026, to seek shareholder approval for a board appointment. The main agenda is the appointment of Ms. Jasmin Kunal Tailor as an Independent Director for a three-year term effective from November 09, 2025. Shareholders registered as of the cut-off date, January 30, 2026, are entitled to vote. The remote e-voting facility will be open from February 04 to February 06, 2026.

EGM to be held on February 07, 2026, at 11:00 A.M. via Video Conferencing.
Appointment of Ms. Jasmin Kunal Tailor as Independent Director for a 3-year term until Nov 2028.
Cut-off date for determining voting eligibility is January 30, 2026.
Remote e-voting window is active from Feb 04 (9:00 AM) to Feb 06 (5:00 PM), 2026.

💡 Investors should monitor the outcome of the EGM to ensure the board maintains its required independent composition. No immediate buy or sell action is necessitated by this routine governance update.

Vineet Laboratories: Compliance Certificate Under SEBI Regulation 74(5) for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 06:34 PM

Vineet Laboratories Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by the Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Private Limited, covers the third quarter ended December 31, 2025. It confirms that no securities were received for dematerialization or rematerialization during this period. This is a standard administrative disclosure required for all listed entities in India to ensure accurate shareholding records.

Compliance certificate submitted for the third quarter ended December 31, 2025
Issued by Venture Capital and Corporate Investments Private Limited (RTA)
Confirms zero securities were received for dematerialization or rematerialization during the quarter
Filing adheres to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

💡 This is a routine regulatory filing with no impact on the company's financial performance or business operations. No action is required from investors.

Vineet Laboratories to Appoint Independent Director; EGM Scheduled for February 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 07 Jan 2026, 02:56 PM

Vineet Laboratories Limited has announced an Extra-Ordinary General Meeting (EGM) to seek shareholder approval for the appointment of Ms. Jasmin Kunal Tailor as an Independent Director. The company has established January 09, 2026, as the cut-off date for dispatching the EGM notice and January 30, 2026, for determining voting eligibility. Remote e-voting is scheduled to take place between February 4 and February 6, 2026. This meeting follows the board's approval on January 07, 2026, to strengthen its corporate governance structure.

Appointment of Ms. Jasmin Kunal Tailor (DIN: 10794164) as an Independent Director proposed for shareholder approval.
Cut-off date for sending EGM notice is set for January 09, 2026.
Voting eligibility cut-off date is January 30, 2026, with remote e-voting from February 4 to February 6, 2026.
Board meeting concluded within 40 minutes on January 07, 2026, starting at 2:00 PM.

💡 This is a routine governance update regarding board composition. Investors do not need to take any immediate action but should stay informed of the EGM voting results.

Vineet Laboratories Announces Trading Window Closure for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Dec 2025, 02:09 PM

Vineet Laboratories Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. The closure is ahead of the declaration of the standalone un-audited financial results for the third quarter ending December 31, 2025. The window will remain closed for all designated persons and their relatives until 48 hours after the results are made public. The company has also implemented PAN freezing for designated persons during this period as per SEBI guidelines.

Trading window closure effective from January 1, 2026.
Closure pertains to the financial results for the quarter ending December 31, 2025.
Window to reopen 48 hours after the announcement of Q3 results.
PAN freezing of Designated Persons (DPs) ensured as per SEBI circular dated July 19, 2023.
Board meeting date for result declaration to be announced in due course.

💡 This is a routine regulatory filing with no direct impact on stock fundamentals. Investors should wait for the announcement of the board meeting date to review the company's Q3 performance.

Vineet Laboratories to Raise ₹29.97 Crore via Rights Issue at ₹30 Per Share

🟡 NEUTRAL ⭐ 8/10

FUNDRAISE 📅 20 Dec 2025, 02:30 PM

Vineet Laboratories Limited has submitted its Letter of Offer for a Rights Issue aiming to raise approximately ₹29.97 crore. The company will issue 99,87,258 equity shares at a price of ₹30 per share, which includes a premium of ₹20. The rights entitlement ratio is fixed at 13 shares for every 12 shares held by eligible shareholders as of the record date, December 23, 2025. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.

Rights issue size of up to 99,87,258 shares aggregating to ₹29.97 Crores
Issue price set at ₹30 per share (Face Value ₹10 + Premium ₹20)
Rights entitlement ratio of 13:12 for shareholders as of December 23, 2025
Subscription period opens on January 01, 2026, and closes on January 21, 2026
On-market renunciation period ends on January 16, 2026

💡 Existing shareholders should monitor the market price relative to the ₹30 offer price and decide whether to subscribe, renounce, or sell their rights entitlements before the January 16 deadline.

View All VINEETLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue from operations fell 50.2% YoY from INR 150.59 Cr in FY24 to INR 74.99 Cr in FY25. Segment-specific growth percentages were not disclosed, but the company primarily operates in API intermediates.

Geographic Revenue Split

100% Domestic revenue in FY25 as foreign exchange earnings were reported as Nil, compared to a previous year where exports were a focus for the broader industry.

Profitability Margins

Net Profit Margin plummeted from 0.68% in FY24 to -26.92% in FY25. Operating Profit Margin also turned negative, dropping from 0.68% to -0.25% YoY.

EBITDA Margin

Operating Profit Margin was -0.25% in FY25, down from 0.68% in FY24, reflecting a core profitability collapse due to the 50.2% drop in revenue.

Capital Expenditure

Not explicitly disclosed in INR Cr, but the company is pursuing a Rights Issue to address financial modalities and capital requirements.

Credit Rating & Borrowing

Not disclosed, but the Interest Coverage Ratio worsened significantly from 1.28 to -4.72, indicating the company cannot meet interest obligations from current earnings.

⚙️ Operational Drivers

Raw Materials

Intermediate raw materials including 2-Amino-5-(S)-N,N-Dibenzyl Amino-3-Oxo-1,6-Diphenylhex-2-Ene (DAH-II) and 5-Hydroxy Methyl Thiazole.

Import Sources

China (industry-wide 80% dependency for API needs mentioned as a critical factor).

Key Suppliers

Vineet Life Sciences Private Limited (Related Party) provides intermediate raw material supplies.

Capacity Expansion

Current installed capacity not disclosed in MT; however, the company is seeking to raise capital via a Rights Issue to support operations.

Raw Material Costs

Not disclosed as a specific percentage of revenue, but related party transactions for sale and purchase of goods are ongoing at arm's length.

Manufacturing Efficiency

Inventory turnover ratio declined by 40.7% from 2.38 to 1.41, indicating reduced manufacturing and sales efficiency.

📈 Strategic Growth

Expected Growth Rate

5.30%

Growth Strategy

The company plans to achieve growth by leveraging the global 5.3% CAGR in pharmaceutical intermediates, focusing on high-demand anti-HIV drug intermediates like DAH-II and 5-Hydroxy Methyl Thiazole, and improving its capital structure through a proposed Rights Issue.

Products & Services

API intermediates including DAH-II (for Lopinavir API) and 5-Hydroxy Methyl Thiazole (for Ritonavir API).

Market Expansion

Not disclosed, though industry-wide expansion into new geographies like Montenegro and South Sudan is noted.

Market Share & Ranking

Not disclosed; Indian pharma industry ranks 3rd globally by volume and 13th by value.

Strategic Alliances

MoU between Indian Pharmacopoeia Commission and Suriname for recognition of Indian standards; company-specific alliances not disclosed.

🌍 External Factors

Industry Trends

Global intermediates market growing at 5.3% CAGR; shift from batch to continuous manufacturing to improve quality; government support via PRIP (INR 5,000 Cr) and PLI (INR 15,000 Cr) schemes.

Competitive Landscape

Intense competition from Chinese manufacturers and other domestic MSMEs in the bulk drug and intermediate segments.

Competitive Moat

Cost-efficient production and high-quality generic drugs; India has the highest number of USFDA-approved plants outside the US, providing a structural advantage.

Macro Economic Sensitivity

Highly sensitive to global chronic disease prevalence, which is expected to increase by 57% by 2020 (as per WHO data cited).

Consumer Behavior

Aging global population and rising chronic disease prevalence are driving long-term demand for pharmaceutical intermediates.

Geopolitical Risks

Trade barriers or policy changes in China could disrupt 80% of the API supply chain.

⚖️ Regulatory & Governance

Industry Regulations

Strict compliance with GMP, WHO standards, and USFDA requirements for manufacturing plants.

Environmental Compliance

Compliance with Good Manufacturing Practices (GMP) is mandatory; no specific ESG costs disclosed for FY25.

Taxation Policy Impact

Not disclosed; company reported a tax benefit/adjustment resulting in PAT of INR -20.19 Cr vs PBT of INR -20.77 Cr.

⚠️ Risk Analysis

Key Uncertainties

Financial insolvency risk due to negative interest coverage (-4.72); 80% dependency on China for raw materials; liquidity risk with a current ratio of 0.91.